Results using Alpha IMS subretinal Implant for Retinitis Pigmentosa published in Vision Research-Retina Implant

Retina Implant AG has announced the publication of data from the Company's global clinical trial involving seven sites across five countries, on results of 29 late-stage Retinitis Pigmentosa and cone-rod dystrophy patients implanted with the Alpha IMS subretinal implant.

The study shows that more than 86 percent of patients implanted with the 3x3 mm2 device with 1,500 electrodes experienced improved ability to detect light, including the identification of specific light sources. In addition, nearly half of the 29 previously blind study patients reported restoration of useful visual experiences in daily life, including the recognition of shapes and household objects, improved ability to identify facial features and some of them even the ability to read letters.